1. Home
  2. ASMB vs ARMP Comparison

ASMB vs ARMP Comparison

Compare ASMB & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • ARMP
  • Stock Information
  • Founded
  • ASMB 2005
  • ARMP N/A
  • Country
  • ASMB United States
  • ARMP United States
  • Employees
  • ASMB N/A
  • ARMP N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • ARMP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ASMB Health Care
  • ARMP Health Care
  • Exchange
  • ASMB Nasdaq
  • ARMP Nasdaq
  • Market Cap
  • ASMB 84.5M
  • ARMP 80.0M
  • IPO Year
  • ASMB 2010
  • ARMP N/A
  • Fundamental
  • Price
  • ASMB $13.42
  • ARMP $2.08
  • Analyst Decision
  • ASMB Buy
  • ARMP Strong Buy
  • Analyst Count
  • ASMB 2
  • ARMP 1
  • Target Price
  • ASMB $35.00
  • ARMP $7.00
  • AVG Volume (30 Days)
  • ASMB 22.6K
  • ARMP 7.1K
  • Earning Date
  • ASMB 03-27-2025
  • ARMP 03-20-2025
  • Dividend Yield
  • ASMB N/A
  • ARMP N/A
  • EPS Growth
  • ASMB N/A
  • ARMP N/A
  • EPS
  • ASMB N/A
  • ARMP N/A
  • Revenue
  • ASMB $28,326,000.00
  • ARMP $5,467,000.00
  • Revenue This Year
  • ASMB $282.16
  • ARMP $23.87
  • Revenue Next Year
  • ASMB N/A
  • ARMP N/A
  • P/E Ratio
  • ASMB N/A
  • ARMP N/A
  • Revenue Growth
  • ASMB N/A
  • ARMP 34.92
  • 52 Week Low
  • ASMB $9.84
  • ARMP $1.80
  • 52 Week High
  • ASMB $19.93
  • ARMP $4.48
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 40.25
  • ARMP 51.22
  • Support Level
  • ASMB $13.60
  • ARMP $1.97
  • Resistance Level
  • ASMB $14.25
  • ARMP $2.12
  • Average True Range (ATR)
  • ASMB 0.58
  • ARMP 0.11
  • MACD
  • ASMB -0.05
  • ARMP -0.00
  • Stochastic Oscillator
  • ASMB 5.93
  • ARMP 27.50

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Share on Social Networks: